Analyst Rating Update on Astrazeneca PLC (AZN)

Astrazeneca PLC (AZN) : 1 brokerage houses believe that Astrazeneca PLC (AZN) is a Strong Buy at current levels. 3 analysts believe that the current prices are in a balance with the stocks fundamentals, hence they propose Hold on Astrazeneca PLC (AZN). Zacks Investment Research suggests a Hold with a rank of 3.The median of all the 4 Wall Street Analysts endorse the stock as a Buy with a rating of 2.5.

Astrazeneca PLC (AZN) : Currently there are 3 street experts covering Astrazeneca PLC (AZN) stock. The most bullish and bearish price target for the stock is $38 and $35 respectively for the short term. The average price target of all the analysts comes to $36.17. The estimated standard deviation from the target is $1.26.

Company shares have received an average consensus rating of Hold for the current week Also, Argus Research initiates coverage on Astrazeneca PLC (NYSE:AZN). The rating major has initiated the coverage with hold rating on the shares. The rating by the firm was issued on July 12, 2016.


Astrazeneca PLC (NYSE:AZN): The stock opened at $33.76 on Wednesday but the bulls could not build on the opening and the stock topped out at $34.26 for the day. The stock traded down to $33.76 during the day, due to lack of any buying support eventually closed down at $34.09 with a loss of -0.35% for the day. The stock had closed at $34.21 on the previous day. The total traded volume was 9,400,315 shares.

AstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company. The Company discovers, develops and commercializes prescription medicines for cardiovascular and metabolic diseases; oncology; respiratory, inflammation and autoimmunity, and infection, neuroscience and gastrointestinal. Its medicines include Crestor for managing cholesterol levels; Seloken/Toprol-XL for hypertension, heart failure and angina; Iressa for lung cancer; Faslodex for breast cancer; Zoladex for prostate and breast cancer; Nexium for acid-related diseases; Seroquel XR for schizophrenia, bipolar disorder and depressive disorder, and Synagis for RSV (respiratory syncytial virus), a respiratory infection in infants. It also offers potassium-binding compound sodium zirconium cyclosilicate (ZS-9), a treatment for hyperkalaemia, a condition associated with increased mortality in patients with chronic kidney disease (CKD), diabetes mellitus (DM) and chronic heart failure (CHF).

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.